Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications
03 Décembre 2007 - 3:15PM
PR Newswire (US)
RICHMOND, Va., Dec. 3 /PRNewswire-FirstCall/ -- Insmed Inc.
(NASDAQ:INSM), a biopharmaceutical company, announced today that it
has retained FD and Gibraltar Associates to provide investor
relations and corporate communications services, respectively. FD
and Gibraltar intend to offer an integrated program to highlight
Insmed's role as a pioneer and leader in the emerging field of
follow-on biologics and to increase the Company's institutional
investor visibility. "With the characterization of our first two
follow-on biologics now completed and positioned for clinical
studies, Insmed is at the forefront of a rapidly emerging field
with significant growth potential," said Geoffrey Allan, CEO of
Insmed. "We believe this is the right time to launch a
comprehensive communications plan to identify high-quality
institutional investors, and successfully position Insmed's
investment thesis. Working with FD and Gibraltar provides us with
elite talent and expertise in investor and public relations. We are
turning to them to help us to tell our story and maximize
shareholder value." "We believe our life sciences expertise and
knowledge of the public markets are an excellent strategic fit for
Insmed, and we look forward to working with Insmed's management
team and Gibraltar Associates," said Jonathan Birt, Managing
Director of the Healthcare & Life Sciences practice at FD. "FD
has an extensive track record in working with the world's leading
scientific and medical companies, and we are pleased to have the
opportunity to support Insmed at such an important stage of its
development." "Our experience in repositioning corporate brands,
navigating public affairs challenges, and unlocking shareholder
value promises to create a successful partnership with Insmed,"
said Eric Bovim, CEO of Gibraltar Associates. "We look forward to
working with Insmed and FD in communicating the substantial market
potential for follow-on biologics, and highlighting Insmed's unique
position in the industry." Headquartered in Richmond, Virginia,
Insmed is at the forefront of the development of follow-on
biologics. The Company has an FDA-approved biologics commercial
manufacturing facility in Boulder, Colorado, and has significantly
expanded its comprehensive capabilities in the characterization,
development and manufacturing of follow-on biologics. Insmed
recently completed the characterization of its first two follow-on
biologics, INS-19 (Granulocyte Colony Stimulating Factor or G-CSF)
and INS-20 (Peg G-CSF), both for the treatment of neutropenia. The
Company intends to initiate clinical studies on these product
candidates in 2008. Insmed is also continuing to advance its
proprietary protein platform into niche markets with unmet needs.
Insmed's lead product in this area is IPLEX(TM), which previously
received FDA approval for the treatment of severe primary IGF
deficiency, and is currently in clinical development for Myotonic
Muscular Dystrophy (MMD), ALS (Lou Gehrig's Disease) and
HIV-Associated Adipose Redistribution Syndrome (HARS). About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein
process development and manufacturing experience and a proprietary
protein platform aimed at niche markets with unmet medical needs.
For more information, please visit http://www.insmed.com/. About FD
As the world's most sought-after business and financial
communications consultancy, FD helps the world's leading
organizations harness the power of communications to solve critical
business challenges that threaten their brand, reputation and
valuation. Named PR Week's 2006 "International Consultancy of the
Year," FD's 500 professionals advise clients from 17 offices in
every major business center in the world. FD is a division of FTI
Consulting (NYSE:FCN), a global corporate advisory firm
specializing in helping clients overcome complex business
challenges in areas such as restructuring, litigation, mergers and
acquisitions, regulatory investigations, and reputation management,
among many others. For more information, please visit
http://www.fd.com/. About Gibraltar Associates Gibraltar Associates
is a consultancy specializing in risk and reputation management,
public affairs and business development for clients worldwide.
Gibraltar Associates blends expertise from diverse consulting
genres to offer clients a truly holistic approach to solving
challenges confronting the business. Our mission is to provide
world-class counsel to clients and implement those ideas to produce
a tangible business result. The company is based in Washington,
D.C., with an office in Los Angeles. For more information, please
visit: http://www.gibraltar-llc.com/ or call 202-879-5808.
Forward-Looking Statements This release contains forward-looking
statements which are made pursuant to provisions of Section 21E of
the Securities Exchange Act of 1934. Investors are cautioned that
such statements in this release, including statements relating to
planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for
existing or proposed products, constitute forward-looking
statements which involve risks and uncertainties that could cause
actual results to differ materially from those anticipated by the
forward-looking statements. The risks and uncertainties include,
without limitation, risks that product candidates may fail in the
clinic or may not be successfully marketed or manufactured, we may
lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies
differently than us, competing products may be more successful,
demand for new pharmaceutical products may decrease, the
biopharmaceutical industry may experience negative market trends,
our entrance into the follow on biologics market may be
unsuccessful, our common stock could be de-listed from the Nasdaq
Global Market and other risks and challenges detailed in our
filings with the U.S. Securities and Exchange Commission, including
our Quarterly Report on Form 10-Q for the quarter ended September
30, 2007. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. We undertake no obligation to publicly release the results
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances that occur after the date
of this release or to reflect the occurrence of unanticipated
events. DATASOURCE: Insmed CONTACT: Investors, Brian Ritchie of FD,
+1-212-850-5683, , for Insmed; or Media, John Procter of Gibraltar
Associates, +1-202-879-5808, , for Insmed Web site:
http://www.insmed.com/ http://www.fd.com/
http://www.gibraltar-llc.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024